Iambic Therapeutics, Inc.’s Quiet Period Set To Expire on November 24th (NASDAQ:IAM)

Iambic Therapeutics’ (NASDAQ:IAM – Get Free Report) quiet period is set to end on Tuesday, November 24th. Iambic Therapeutics had issued 9,375,000 shares in its public offering on October 15th. The total size of the offering was $150,000,000 based on an initial share price of $16.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

IAM has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Citigroup began coverage on Iambic Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $22.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on Iambic Therapeutics in a report on Monday, November 9th. They set an “overweight” rating and a $22.00 price objective on the stock. Jefferies Financial Group initiated coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Bank of America began coverage on Iambic Therapeutics in a report on Monday, November 9th. They set a “buy” rating and a $30.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.25.

Read Our Latest Stock Analysis on Iambic Therapeutics

Iambic Therapeutics Stock Up 3.8%

NASDAQ:IAM opened at $14.76 on Thursday. Iambic Therapeutics has a 1-year low of $9.60 and a 1-year high of $25.00.

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($6.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($5.90). The business had revenue of $11.35 million during the quarter, compared to analyst estimates of $42.50 million. On average, equities analysts anticipate that Iambic Therapeutics will post -1.79 EPS for the current year.

Insider Buying and Selling at Iambic Therapeutics

In other Iambic Therapeutics news, Director Evan Lockwood Rachlin bought 718,750 shares of the company’s stock in a transaction dated Friday, October 16th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the acquisition, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 22.90% of the stock is owned by corporate insiders.

About Iambic Therapeutics

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

See Also

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.